NCT00316875View on ClinicalTrials.gov

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Breast Cancer
Interventions
DRUG

lapatinib ditosylate

1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).

DRUG

Doxil

Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule

Trial Locations (1)

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00316875 - Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter